Product Description
Mechanisms of Action: IBAT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Indonesia | Japan | Philippines
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Constipation
Phase 2: Fatty Liver, Alcoholic|Constipation|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06436833 | N/A |
Recruiting |
Abdominal Pain|Diarrhea|Anemia|Weight Loss|Constipation|Chronic Pain|Colorectal Cancer |
2024-11-30 |
|
| TANK-27 | P4 |
Unknown status |
Constipation |
2023-06-30 |
|
| 22-Nr-049 | P4 |
Terminated |
Constipation |
2023-03-03 |
|
| JapicCTI-184007 | N/A |
Active |
Constipation |
2022-12-01 |